Unilateral unique Lupus tumidus: pathogenetic mystery and diagnostic problem
| Autor: | Georgi Tchernev, Anastasiya Atanasova Chokoeva, Ilko Bakardzhiev, Ivan Krasnaliev, Uwe Wollina, Claudio Tana, Torello Lotti |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Adult
Male medicine.medical_specialty Biopsy Lasers Dye Dapsone Tacrolimus Diagnosis Differential Ointments 030207 dermatology & venereal diseases 03 medical and health sciences Lupus Erythematosus Discoid 0302 clinical medicine Adrenal Cortex Hormones Azathioprine Humans Medicine skin and connective tissue diseases Skin 030203 arthritis & rheumatology Reticular erythematous mucinosis Systemic lupus erythematosus business.industry Standard treatment Chloroquine Hydroxychloroquine General Medicine medicine.disease Combined Modality Therapy Dermatology Quinacrine Differential diagnosis business Polymorphous light eruption Sunscreening Agents medicine.drug |
| Zdroj: | Wiener Medizinische Wochenschrift. 166:250-253 |
| ISSN: | 1563-258X 0043-5341 |
| Popis: | Lupus tumidus is a rare immunological disorder whose pathogenesis is not fully understood. Although on the one hand there are some differences in (1) the clinical morphology of lesions, (2) the histopathology picture, as well as in (3) serological profile of lupus tumidus patients at the current moment, the disease is regarded as a subform of chronic cutaneous lupus erythematosus. Differential diagnosis requires the exclusion of many diseases such as Jessner Kanoff lymphocytic infiltration, polymorphous light eruption, and reticular erythematous mucinosis. Differentiation between them is not always easy. The standard treatment regimen of patients with lupus tumidus is based on local and systemic application of corticosteroids, azathioprin, dapsone, mepacrine, chloroquine, and hydroxychloroquine. Modern treatment options include the use of pulsed dye laser, tacrolimus 0.1 % ointment and photophoresis. We present a 42-year-old patient with unilateral atypical form of lupus tumidus who was successfully treated with systematically administration of hydroxychloroquine in combination with sunscreen SPF 50. After a 2-month course of treatment with hydroxychloroquine dosage of 200 mg per day and a break of 3 months between courses, we observed a complete remission. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink